Pediatric hidradenitis suppurativa: epidemiology, disease presentation, and treatments
- PMID: 34057384
- PMCID: PMC9847248
- DOI: 10.1080/09546634.2021.1937484
Pediatric hidradenitis suppurativa: epidemiology, disease presentation, and treatments
Conflict of interest statement
Disclosure statement
J. L. H. is on the Board of Directors for the Hidradenitis Suppurativa Foundation and has served as an advisor for Novartis and a speaker for AbbVie. V. Y. S. is on the Board of the Directors for the Hidradenitis Suppurativa Foundation, and has served as an advisor, investigator and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt’s Bees, Dermira, Eli Lilly, Novartis, Pfizer, Galderma, Leo Pharma, SUN Pharma, Menlo Therapeutics, GpSkin, and Skin Actives Scientific. M. H. is an investigator for Amgen and Celgene. J. R. S., E. K. C., T. G., and T. S. report no conflicts of interest. There was no financial transaction for the preparation of this manuscript. No potential conflict of interest was reported by the author(s).
References
-
- Savage KT, Gonzalez BE, Flood KS, et al. Publication trends in hidradenitis suppurativa from 2008 to 2018. J Eur Acad Dermatol Venereol. 2020;34(9):1885–1889. - PubMed
-
- Riis PT, Saunte DM, Sigsgaard V, et al. Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients. Arch Dermatol Res. 2020;312(10):715–724. - PubMed
-
- Braunberger TL, Nicholson CL, Gold L, et al. Hidradenitis suppurativa in children: the Henry Ford experience. Pediatr Dermatol. 2018;35(3):370–373. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical